Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Advanced Epithelial Cancer
NCT01631552Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2012
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in gastric adenocarcinoma, esophageal cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Gilead Sciences. Started Dec 2012; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
gastric adenocarcinomaesophageal cancerhepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01631552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01631552.